KYMBEE (deflazacort)
Duchenne Muscular Dystrophy (DMD)
ApprovedActive
Key Facts
About Upsher-Smith
Upsher-Smith is a century-old, trusted U.S. pharmaceutical company operating as a commercial-stage entity with a hybrid portfolio of branded and generic drugs. Following its acquisition by Bora Pharmaceuticals in April 2024 and subsequent merger with TWi Pharmaceuticals, it has strengthened its pipeline and expanded its product offerings, particularly in neurology and rare diseases. The company's strategy focuses on strategic acquisitions, partnerships, and a commitment to reliable supply to serve patients with cost-effective therapies.
View full company profileTherapeutic Areas
Other Duchenne Muscular Dystrophy (DMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| DT-DEC01 | Dystrogen Therapeutics | Phase 1 |
| Skeletal Muscle Regeneration Program | IPS HEART | Pre-clinical |
| ALY688ER | Allysta Pharmaceuticals | Phase 1 |
| AVGN7 + AVGND | AAVogen | Pre-clinical |
| Myomatrix Stabilization Program | Strykagen | Preclinical |
| RIPPLE™ (implied) | SonoThera | Preclinical |
| Vamorolone (AGAMREE) | ReveraGen BioPharma | Approved |
| AGAMREE (vamorolone) | Catalyst Pharmaceuticals | Marketed |
| EDG-5506 | Edgewise Therapeutics | Phase 2 |
| ELEVIDYS (delandistrogene moxeparvovec-rokl) | Sarepta Therapeutics | Marketed / Phase 3 |
| SRP-5051 (vesleteplirsen) | Sarepta Therapeutics | Phase 2 |
| EXONDYS 51 (eteplirsen) | Sarepta Therapeutics | Marketed |